Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy
Metrics: PDF 4146 views | HTML 7955 views | ?
Mao-Bin Meng1,*, Huan-Huan Wang1,*, Yao-Li Cui2,*, Zhi-Qiang Wu1, Yang-Yang Shi3, Nicholas G. Zaorsky4, Lei Deng5, Zhi-Yong Yuan1, You Lu5 and Ping Wang1
1 Department of Radiation Oncology, Tianjin’s Clinical Research Center for Cancer and Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China
2 Department of Lymphoma, Tianjin’s Clinical Research Center for Cancer and Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China
3 Stanford University School of Medicine, Stanford, CA, United States of America
4 Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States of America
5 Department of Thoracic Cancer and Huaxi Student Society of Oncology Research, West China Hospital, West China School of Medicine, Sichuan University, Sichuan Province, China
* These authors have contributed equally to this work
Mao-Bin Meng, email:
Keywords: necroptosis; tumorigenesis; anti-tumor immune; cancer therapy
Received: April 05, 2016 Accepted: June 20, 2016Published: July 12, 2016
While the mechanisms underlying apoptosis and autophagy have been well characterized over recent decades, another regulated cell death event, necroptosis, remains poorly understood. Elucidating the signaling networks involved in the regulation of necroptosis may allow this form of regulated cell death to be exploited for diagnosis and treatment of cancer, and will contribute to the understanding of the complex tumor microenvironment. In this review, we have summarized the mechanisms and regulation of necroptosis, the converging and diverging features of necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy, as well as attempts to exploit this newly gained knowledge to provide therapeutics for cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.